Biogen Inc. (NASDAQ:BIIB)’s recent partnership with City Therapeutics, Inc. to develop RNAi therapies for central nervous system diseases has fueled a 6% rise in its share price over the past ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the ...

BIIB stands above RGEN thanks to its solid earnings outlook, and based on these valuation figures, we also feel that BIIB is the superior value option right now.

BIIB sticks out from RGEN in both our Zacks Rank and Style Scores models, so value investors will likely feel that BIIB is the better option right now. Infrastructure Stock Boom to Sweep America ...